Yu Zhao | Crop developmental biology | Best Researcher Award

Posted on by sciencefather

Dr. Yu Zhao | Crop developmental biology | Best Researcher Award

Professor at Huazhong Agricultural University, China

Professor Yu Zhao is a distinguished scientist and academic leader in the field of plant molecular biology, with a focus on rice developmental biology. As a renowned researcher, she has made groundbreaking contributions to understanding the genetic and epigenetic regulation of crown root development in rice. Her innovative work explores how plants adapt to environmental challenges, ultimately aiming to improve crop resilience and productivity. With a prolific publication record in leading scientific journals, Professor Zhao continues to be a driving force in agricultural biotechnology.

Profile

Orcid

Education

Professor Zhao earned her Ph.D. in Plant Biology, where she developed a solid foundation in molecular genetics and developmental biology. During her doctoral studies, she began investigating the regulatory networks involved in root architecture, laying the groundwork for her future research in rice morphogenesis. Her academic training integrated advanced genomic technologies and epigenetic tools, preparing her to explore complex plant development mechanisms. Over the years, she has enriched her expertise through continued learning and collaboration across international research institutions.

Experience

Currently serving as a Professor at the National Key Laboratory of Crop Genetic Improvement, Professor Zhao leads a dynamic research team focused on rice organogenesis. With a career spanning over a decade in plant molecular biology, she has mentored numerous graduate students and postdoctoral fellows, fostering a collaborative and innovative research environment. Her experience encompasses gene expression analysis, chromatin remodeling, and high-throughput genomic approaches. She plays a pivotal role in national crop improvement initiatives and frequently contributes to international symposia and collaborative projects aimed at advancing food security.

Research Interest

Professor Zhao’s research centers on the molecular mechanisms governing crown root development in rice, which is vital for anchorage and nutrient uptake. She is particularly interested in how transcription factors such as WOX11, LBD16, and ERF3, along with chromatin modifiers like histone acetyltransferases and demethylases, control root initiation and elongation. Her studies also examine how environmental stresses, including heat and cold, influence root system development at the epigenetic level. Using approaches such as spatial transcriptomics and methylome profiling, her lab elucidates how rice plants adapt their root architecture to changing environments, with the goal of designing resilient crop varieties.

Award

Professor Zhao has received multiple honors for her exceptional contributions to plant science. Her innovative research has not only advanced theoretical understanding but also yielded practical solutions for crop improvement. She holds several national and international patents related to key regulatory genes in rice development and stress adaptation. These patents reflect her commitment to translational research and her ability to convert fundamental discoveries into applicable technologies for sustainable agriculture.

Publication

Professor Zhao has authored numerous influential publications. Below are seven selected peer-reviewed papers that exemplify the breadth and impact of her work:

  1. Ma et al. (2025), Nature Plants – Demonstrated the regulation of OsECT3 via lysine acetylation under cold stress in rice. (Cited by 21 articles)
  2. Zhang et al. (2025), New Phytologist – Explored the uORF-HsfA1a-WOX11 pathway in crown root development. (Cited by 18 articles)
  3. Zhong et al. (2025), Molecular Plant – Identified spatial transcriptomic adaptations in rice roots under dryland conditions. (Cited by 30 articles)
  4. Geng et al. (2024), Plant Cell – Revealed the cooperation of WOX11, LBD16, and JMJ706 in root development. (Cited by 42 articles)
  5. Chen et al. (2024), Cell Reports – Linked histone deacetylase activity to heat stress tolerance in rice. (Cited by 25 articles)
  6. Liu et al. (2023), Nature Communications – Reported DNA methylation reprogramming in the rice zygote. (Cited by 50 articles)
  7. Li et al. (2023), EMBO Journal – Unveiled chromatin modification mechanisms behind DELLA-mediated repression. (Cited by 33 articles)

These publications, many co-authored with global experts in plant genetics, demonstrate Professor Zhao’s leadership in both fundamental and applied plant biology.

Conclusion

In conclusion, Professor Yu Zhao is a visionary female scientist whose career exemplifies excellence in research, innovation, and mentorship. Her extensive contributions to understanding rice root development and environmental adaptation have far-reaching implications for crop improvement and global food sustainability. As a thought leader in plant epigenetics and developmental biology, she bridges the gap between laboratory research and agricultural application. Her dedication to translational science, strong publication record, and portfolio of patented technologies make her an outstanding candidate for prestigious recognitions in biotechnology and plant science research.

Gilles Pagès | Breast Cancer | Best Researcher Award

Posted on by sciencefather

Dr. Gilles Pagès | Breast Cancer | Best Researcher Award

Director of Research exceptional class at INSERM, France

Dr. Gilles Pagès is a senior cancer research scientist with a long-standing career in molecular and cellular biology, prominently contributing to oncology through translational and experimental research. Currently a DRCE-level researcher at INSERM and principal investigator at IRCAN, he also serves as a consultant to the Centre Scientifique de Monaco. Since completing his PhD in 1990 and his habilitation in 1994 at the University of Nice, he has consistently worked at the intersection of angiogenesis, resistance mechanisms in cancer therapy, and vascular biology. Dr. Pagès holds an international reputation, underscored by memberships in key scientific boards and a prolific record of publications, grants, and patents.

profile

Orcid

Education:

Dr. Pagès received his PhD in molecular and cellular biology in 1990 from Nice, France, and earned his Habilitation à diriger des recherches in 1994. His early academic trajectory was marked by a steady rise through French research ranks, ultimately achieving the highest level as DRCE at INSERM in 2024. His solid foundational education and continuous professional advancement have positioned him as an expert in translational cancer research.

Experience:

From 1990 to 2007, he served as Assistant Professor, progressing to DR2 INSERM (2007–2013), DR1 INSERM (2013–2023), and finally DRCE INSERM from 2024. At IRCAN, Dr. Pagès has led innovative cancer research and contributed extensively to mentorship and institutional development. He is also a consultant for the Centre Scientifique de Monaco and has acted as an expert for pharmaceutical companies such as Roche, Bayer, Ipsen, and BMS. His international influence is reflected in invitations to over 30 scientific conferences and roles in organizing major congresses like the Biennale de Cancérologie de Monaco.

Research Interests:

Dr. Pagès’ research focuses on tumor angiogenesis, resistance to anti-angiogenic therapy, the tumor microenvironment, renal cell carcinoma, and therapeutic targeting of cytokine and chemokine pathways. He has contributed significantly to understanding CXCL-CXCR signaling, neuropilins, and metabolic vulnerabilities in cancer. His team investigates translational approaches that link mechanistic insights with clinical applications, bridging gaps between bench and bedside.

Awards:

His pioneering work has garnered several accolades, including the Grand Prix Ruban Rose for breast cancer research (2015), the Prince Albert I° Award from the National Academy of Medicine (2018), the Amgen Foundation Award (2021), and the prestigious Grand Prix Jean Valade from Fondation de France (2023–2024). These honors underscore his contributions to advancing cancer research and therapeutic innovation.

Publications:

Dr. Pagès has authored over 160 publications and holds 14 patents. Below are 7 selected key publications:

  1. Teisseire M et al., 2025, Cancer Research: “De Novo Serine Synthesis is a Metabolic Vulnerability that can be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma” – This study, cited in 12 articles, explores therapeutic resistance mechanisms in renal cancer.
  2. Sarlak S, Pagès G, Luciano F, 2025, Cancer Treatment Reviews: “Enhancing radiotherapy techniques for Triple-Negative Breast Cancer” – A collaborative review shaping future radiotherapy strategies.
  3. Sirera J et al., 2024, Journal of Experimental & Clinical Cancer Research: “Disrupting USP39 deubiquitinase function…” – Cited in 20+ papers, it offers novel pathways in myeloma treatment.
  4. Montemagno C et al., 2024, J Exp Clin Cancer Res: “CXCR2 as a therapeutic target in renal cell carcinoma” – Received significant attention with over 30 citations.
  5. Montemagno C et al., 2023, Molecular Oncology: “VEGF splice variants as therapeutic targets” – A foundational paper in RCC therapy cited by leading cancer biologists.
  6. Giuliano S et al., 2023, Autophagy: “Autolysosomal defects in Alzheimer and Parkinson disease” – Cross-disciplinary impact with 18 citations.
  7. Brest P et al., 2023, British Journal of Cancer: “Checkpoint inhibitors and anti-angiogenic agents: a winning combination” – Widely cited for its relevance in immunotherapy integration.

Conclusion:

Dr. Gilles Pagès stands as a distinguished figure in cancer biology, contributing extensively to both basic research and its clinical translation. With a career that spans over three decades, his work bridges molecular insights with therapeutic advances, particularly in renal cell carcinoma and angiogenesis. His strategic involvement in research networks, mentorship, teaching, and startup creation reflects his commitment to innovation and collaboration. Dr. Pagès continues to lead impactful projects, publish influential research, and inspire new generations of scientists across Europe and beyond.

Lingfei Han | Gynecologic Oncology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. lingfei han | gynecologic oncology | Best Researcher Award

Associate professor at Tongji university, China

Lingfei Han is a dedicated medical professional and accomplished researcher in the field of gynecological oncology. Currently serving as an attending surgeon and instructor at the Shanghai First Maternity and Infant Hospital affiliated with Tongji University School of Medicine, Han has cultivated a dual career in both clinical practice and biomedical research. With a strong foundation in clinical medicine and molecular biology, he has developed a specialized focus on cancer immunotherapy, tumor microenvironment, and immunoregulatory pathways relevant to cervical and ovarian cancers. His extensive experience in translational oncology has led to multiple impactful publications and research projects supported by national funding agencies.

Profile

Scopus

Education:

Lingfei Han pursued his medical education entirely at Tongji Medical College of Huazhong University of Science and Technology, where he earned his Bachelor of Medicine degree in Clinical Medicine in 2003. He subsequently deepened his understanding of disease mechanisms through a Master of Science degree in Molecular Biology, completed in 2006. Motivated by a growing interest in gynecologic malignancies, he undertook doctoral studies in Gynecological Oncology and obtained his Ph.D. in 2009. This academic trajectory provided a robust scientific and clinical foundation for his future career in oncologic surgery and immunotherapy research.

Experience:

Since July 2009, Han has been part of the OB/GYN Department at the Shanghai First Maternity and Infant Hospital, beginning his tenure as a resident surgeon and advancing to the position of attending surgeon. Over the years, he has developed proficiency in a range of surgical techniques and has been actively involved in the care and treatment of patients with gynecological cancers. Alongside his clinical responsibilities, he has served as an instructor, mentoring medical students and junior clinicians while continuously participating in laboratory-based cancer research projects.

Research Interest:

Han’s research primarily focuses on the immunological aspects of gynecological cancers, especially cervical and ovarian cancers. He has developed expertise in molecular and cell biology techniques, including recombinant adeno-associated virus construction, flow cytometry, and immunohistochemistry. His major research interests include the immune escape mechanisms in cancer via pathways such as BTLA-HVEM and PD-1/PD-L1 signaling, the development of in vivo tumor models, and cancer gene therapy strategies. Notably, his work includes the use of animal models to simulate metastatic progression and immune modulation, as well as the development of gene panels and nanomedicine platforms for targeted cancer therapy.

Awards:

Lingfei Han has been the recipient of several prestigious research grants and recognitions throughout his career. His notable funded projects include the study of soluble BTLA’s role in immune surveillance evasion in cervical cancer, supported by the Natural Science Foundation of China (2011–2013), and an investigation into its mechanisms in ovarian cancer, funded by the Youth Science and Technology Phosphorus Program of Shanghai. Additionally, his early career promise was acknowledged through Tongji University’s Youth Outstanding Personnel Training Plan grant for exploring BTLA-HVEM signaling in immune escape (2009–2011).

Publications:

Han has authored and co-authored numerous impactful scientific articles. Selected publications include:

  1. EIF4A3-regulated circ_0087429 reverses EMT in cervical cancer via miR-5003-3p/OGN axis, J Exp Clin Cancer Res, 2022 (Cited by over 40 articles).
  2. Myeloid-derived suppressor cells interact with B10 cells via BAFF/BAFF-R in cervical cancer, Cancer Immunol Immunother, 2022 (Cited by 30+).
  3. A Pyroptosis-Related Gene Panel in Cervical Cancer, Front Oncol, 2022 (Cited by 25).
  4. CMTM6 Overexpression in Ovarian Cancer Immune Infiltration, Front Mol Biosci, 2022 (Cited by 18).
  5. PLGA nanoparticles for co-delivery of drugs in ovarian cancer, Drug Des Devel Ther, 2019 (Cited by 35).
  6. CD163+ and CD68+ macrophages in HPV-related cervical cancer, J Cancer, 2017 (Cited by 50+).
  7. Soluble BTLA boosts HSP70 vaccine-induced tumor immunity, J Immunol, 2009 (Cited by 60+).

Conclusion:

Through a well-balanced integration of clinical care and innovative research, Lingfei Han has made substantial contributions to the understanding and treatment of gynecologic cancers. His work in immune modulation and cancer therapeutics not only advances scientific knowledge but also holds tangible benefits for clinical applications in oncology. His continuous efforts in mentoring, publishing, and research underscore a career committed to translational science and improving patient outcomes. Han’s trajectory demonstrates the importance of a rigorous academic background, interdisciplinary collaboration, and sustained inquiry into cancer immunology.

Naihan Xu | breast cancer research | Best Researcher Award

Posted on by sciencefather

Naihan Xu | breast cancer research | Best Researcher Award

Professor at Shenzhen Polytechnic University, China

Professor Naihan Xu is a leading researcher and educator in the field of tumor biology and molecular medicine, currently serving as a Professor and Doctoral Supervisor at the School of Food and Drug, Shenzhen Polytechnic University. With over two decades of academic and research experience, Dr. Xu has made substantial contributions to understanding cancer pathogenesis and developing targeted therapeutic strategies. Previously, she held a long-term appointment at the Tsinghua Shenzhen International Graduate School of Tsinghua University, where she played a critical role in biopharmaceutical education and translational research. Her academic journey has been marked by dedication to cellular signaling mechanisms, tumor microenvironment regulation, and the development of molecular tools for cancer diagnostics and treatment.

Profile

Scopus

Education

Dr. Xu received her doctoral training in molecular biology and tumor research, supported by an international research fellowship at the prestigious Cancer Research UK Beatson Institute in Glasgow, where she focused on signal transduction in malignancy. Her foundational education laid the groundwork for a robust career in both teaching and research, emphasizing cross-disciplinary approaches that integrate biochemistry, bioinformatics, and molecular diagnostics. This academic background has been pivotal in shaping her research into complex biological systems governing tumor progression and therapy resistance.

Experience

Dr. Xu began her academic career as a lecturer at the Tsinghua Graduate School in Shenzhen in 2010, swiftly rising to Associate Professor and Doctoral Supervisor due to her research productivity and mentoring capacity. From 2011 to 2023, she played a central role at Tsinghua University’s Institute of Biopharmaceutical and Health Engineering, where she supervised numerous doctoral theses and coordinated major grant-funded projects. In 2023, she joined Shenzhen Polytechnic University, where she now leads advanced research on drug discovery and functional diagnostics. Throughout her career, Dr. Xu has fostered interdisciplinary collaborations and contributed to national and international scientific communities.

Research Interest

Her research interests lie at the intersection of tumor biology, signal transduction, and therapeutic innovation. Dr. Xu’s work explores autophagy, tumor metabolism, ubiquitin-proteasome pathways, and cell cycle checkpoints to uncover novel regulatory mechanisms in cancer cells. She is particularly recognized for her focus on non-coding RNAs, peptide-based therapies, and fluorescence-based detection systems. Her studies leverage multi-omics approaches and bioinformatics tools to identify novel molecular targets and understand drug resistance, emphasizing translational impact. Notably, her research extends into precision medicine, using molecular probes and natural small molecules to develop personalized cancer treatments and diagnostic platforms.

Award

Dr. Xu has been the recipient of several prestigious research grants and honors. She has led major projects funded by the National Natural Science Foundation of China (NSFC), including studies on microRNA-regulated autophagy in breast cancer and natural compound inhibitors of DNA damage repair. Additionally, she was recognized by the Shenzhen Science and Technology Innovation Commission through multiple discipline layout and international collaboration projects. Her contributions have positioned her as a prominent figure in the field of cancer signaling research, and she has been nominated for national-level awards for excellence in biopharmaceutical innovation and mentorship.

Publications

Among her extensive body of work, Dr. Xu’s notable publications include:

  1. Genes & Diseases (2025): “Nuclear and cytoplasmic USP30-AS1 coordinately regulates breast cancer progression” – cited by 21 articles.
  2. Inflammation (2024): “USP30-AS1 suppresses colon cancer cell inflammation response through NF-κB/MYBBP1A signaling” – cited by 13 articles.
  3. Biosensors (2024): “Point-of-Care SARS-CoV-2 Detection with Chemiluminescence” – cited by 17 articles.
  4. ACS Applied Materials & Interfaces (2023): “Hybrid Polyplexes for Nucleic Acid Delivery” – cited by 11 articles.
  5. International Journal of Molecular Sciences (2023): “Autophagy-Associated lncRNAs in Neurodegeneration” – cited by 19 articles.
  6. Antioxidants (2023): “Canagliflozin Delays Endothelial Aging via ROS/p38/JNK” – cited by 16 articles.
  7. Frontiers in Immunology (2022): “Exon Screening-Based Prognosis Model in Glioma” – cited by 25 articles.

Each of these contributions reflects Dr. Xu’s sustained focus on mechanistic insights into disease and translational potential in diagnostics or therapeutics.

Conclusion

Dr. Naihan Xu’s scientific trajectory is characterized by a deep commitment to advancing cancer biology through integrative and translational research. Her prolific publication record, successful mentoring of doctoral candidates, and leadership in multi-institutional research initiatives underscore her role as a pivotal figure in China’s biopharmaceutical research landscape. With a forward-looking approach to molecular diagnostics, RNA biology, and therapeutic peptide development, Dr. Xu continues to shape the next generation of oncological research and clinical application. Her nomination for academic and research awards is a recognition of not only her individual excellence but also her enduring impact on scientific innovation and higher education.

Aneliz de Ita Zárate Ortiz | Metabolomics | Young Scientist Award

Posted on by sciencefather

Mrs. Aneliz de Ita Zárate Ortiz | Metabolomics | Young Scientist Award

biologist at Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico

Aneliz de Ita Zárate Ortiz is an emerging researcher specializing in metabolomics and food science, with a strong foundation in molecular biology and fungal biotechnology. Her current work focuses on identifying biomarkers of traditional Mexican food intake and studying lipidomics of animal- and plant-based foods at the National Institute of Medical Sciences and Nutrition Salvador Zubirán. With a robust academic background in biology and practical experience in metabolomics and bioinformatics, she has contributed to scientific literature through studies on fungal species and antifungal metabolites. Aneliz’s academic excellence, hands-on research skills, and commitment to sustainable biotechnology have established her as a promising scientist in the field of microbial metabolomics.

Profile

Orcid

Education

Aneliz holds a Bachelor’s degree in Biology from the Universidad del Mar, Puerto Escondido campus, completed between 2017 and 2023. Her academic journey was marked by high academic achievement, graduating with honors and receiving the highest GPA (9.5) in her cohort. During her undergraduate years, she participated in a social service project investigating fungal diversity along the Oaxaca coast, where she applied DNA sequencing techniques and studied biocontrol fungi. In 2023, she expanded her academic horizons with a research stay at the Center for Scientific Research and Higher Education of Ensenada (CICESE), where she conducted metabolomic analyses of fungi and gained experience in bioinformatic tools for metabolite annotation.

Experience

Since 2024, Aneliz has been conducting research in the metabolomics department at the National Institute of Medical Sciences and Nutrition Salvador Zubirán. Her work focuses on identifying food intake biomarkers from traditional Mexican diets and exploring the lipid profiles of both animal and plant-derived foods. Her earlier research engagements include laboratory analysis of fungal endophytes, DNA sequencing, and biocontrol studies. She has also contributed to national congresses with work on Talaromyces species as microbial antagonists, which demonstrates her growing expertise in fungal biotechnology. Her practical experience encompasses both laboratory techniques and bioinformatic data analysis.

Research Interests

Aneliz’s research interests lie at the intersection of metabolomics, fungal biotechnology, and food science. She is particularly focused on the biochemical profiling of food-derived metabolites and the application of fungal species as biocontrol agents. Her interests also extend to the development of antifungal compounds and the bioinformatic annotation of metabolites. She is committed to integrating traditional food knowledge with modern analytical tools like LC-MS, GNPS, and Sirius for comprehensive metabolomic mapping, with a long-term vision of contributing to public health and sustainable agriculture.

Awards

Aneliz has received notable academic distinctions, including the Best GPA Award in 2022 for her undergraduate generation and the honorary mention upon graduation with her biology degree in 2023. These accolades reflect her dedication to academic excellence and scientific inquiry. Her work has been showcased at multiple national and international congresses, demonstrating her growing influence and recognition within the scientific community. These recognitions underscore her commitment and capability to contribute meaningfully to the fields of biotechnology and metabolomics.

Publications

Aneliz has authored and co-authored several scientific publications in reputable journals:

  1. “Soluciones biotecnológicas: invertebrados salvando nuestros días” (2021), Herreriana, Vol. 3(1), pp. 33–37. [Cited by: 2 articles]
  2. “Talaromyces oaxaquensis sp. nov. section Talaromyces… in Mexico” (2024), Scientia Fungorum, 55, e1457. [Cited by: 3 articles]
  3. “Secretion of antifungal metabolites contributes to the antagonistic activity of Talaromyces oaxaquensis” (2025), Current Research in Microbial Sciences, 100402. [Cited by: 1 article]

These publications highlight her contributions to mycology and microbial metabolite research, particularly in identifying new fungal species and exploring their antifungal properties.

Conclusion

Aneliz de Ita Zárate Ortiz is a dedicated researcher making impactful strides in the fields of metabolomics and microbial biotechnology. Her scientific trajectory, from academic excellence to hands-on research in nationally recognized institutions, demonstrates a well-rounded and promising profile. Her interests in traditional food systems, metabolite identification, and fungal biocontrol agents not only contribute to scientific knowledge but also promote sustainability and public health. As she continues to develop her research career, Aneliz exemplifies the next generation of scientists poised to bridge molecular biology, bioinformatics, and nutritional sciences.

 

Bong-Gyu Mun | Analytical Chemistry | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Bong-Gyu Mun | Analytical Chemistry | Best Researcher Award

Assistant Professor at Chungbuk National University, South Korea

Dr. Bong-Gyu Mun is an accomplished plant biologist and assistant professor at the Department of Environmental and Biological Chemistry, Chungbuk National University. With a strong foundation in plant functional genomics and applied life sciences, Dr. Mun has cultivated an impressive research portfolio focused on plant stress physiology, nano-biotechnology, and sustainable agriculture. His academic trajectory spans over a decade, during which he has significantly contributed to the understanding of plant responses to environmental stresses, particularly through innovative approaches such as the application of nanoparticles, phytohormones, and beneficial microbes. His interdisciplinary work integrates molecular biology, plant physiology, and biochemical studies, earning him recognition in both national and international scientific communities.

Profile

Google Scholar

Education

Dr. Mun earned his Ph.D. in Plant Functional Genomics from Kyungpook National University in August 2017, where he explored the genetic mechanisms governing plant responses to abiotic stresses. He previously received both his Master’s (2012) and Bachelor’s (2010) degrees in Applied Life Science from GyeongSang National University. His academic background has provided him with a robust understanding of the interplay between plant molecular pathways and external environmental stimuli, laying the groundwork for his future research in stress mitigation and crop improvement.

Experience

Dr. Mun’s professional experience encompasses a blend of academic research and applied plant science. Following his Ph.D., he undertook multiple postdoctoral positions at Kyungpook National University and the Temasek Life Sciences Laboratory, where he refined his expertise in agricultural biotechnology and stress physiology. From 2021 to 2023, he served as a research professor at the Institute of Agricultural Science and Technology, focusing on the integration of nanomaterials and plant signaling pathways. In September 2023, he joined Chungbuk National University as an assistant professor, where he continues to pursue cutting-edge research in plant-environment interactions and sustainable crop development.

Research Interest

Dr. Mun’s research interests lie at the intersection of plant molecular biology, environmental stress physiology, and nanotechnology. He is particularly focused on developing strategies to enhance crop resilience under abiotic stresses such as drought, salinity, and heavy metal toxicity. His work includes the use of nanoparticles (e.g., chitosan and GSNO carriers), plant growth-promoting rhizobacteria (PGPR), and natural compounds (e.g., melatonin and fulvic acid) to boost antioxidant defenses and reprogram plant transcriptional responses. Through these innovative approaches, Dr. Mun aims to develop sustainable agricultural practices that improve crop yield and environmental adaptation.

Award

Dr. Mun has been nominated for multiple academic awards and recognitions due to his impactful research contributions in the field of plant stress biology. His interdisciplinary approach, combining genomics, nano-biotechnology, and plant physiology, has led to several high-impact publications and international collaborations. His work is not only academically significant but also offers practical applications in agriculture, contributing to global food security under climate change conditions. His nomination reflects his leadership in research, dedication to academic excellence, and commitment to advancing sustainable agriculture.

Publication

Dr. Mun has authored numerous high-quality research papers, with several published in reputable journals. Selected key publications include:

  1. Enhancing Soybean Salt Tolerance with GSNO and Silicon: A Comprehensive Physiological, Biochemical, and Genetic Study – International Journal of Molecular Sciences, 2025.
  2. Deciphering Whether Illite, a Natural Clay Mineral, Alleviates Cadmium Stress in Glycine max Plants via Modulation of Phytohormones and Endogenous Antioxidant Defense System – Sustainability, 2024.
  3. Brown Garlic: A nutritionally improved garlic with therapeutic value in asthma treatment via modulation of S-Nitrosothiols – Heliyon, 2024.
  4. Chitosan‐fulvic acid nanoparticles enhance drought tolerance in maize via antioxidant defense and transcriptional reprogramming – Physiologia Plantarum, 2024.
  5. Fulvic Acid-releasing Chitosan Nanoparticles Promote the Growth and Drought Stress Tolerance of Rice Plants – Journal of Crop Health, 2024.
  6. Halotolerant Pseudomonas koreensis S4T10 mitigate salt and drought stress in Arabidopsis thaliana – Physiologia Plantarum, 2024.
  7. Chitosan-GSNO nanoparticles: a positive modulator of drought stress tolerance in soybean – BMC Plant Biology, 2023.

These publications have been cited by numerous studies, reflecting the high relevance and scientific impact of his research in plant biotechnology and environmental stress adaptation.

Conclusion

Dr. Bong-Gyu Mun exemplifies the qualities of a forward-thinking researcher committed to solving real-world agricultural challenges through scientific innovation. His extensive education, multifaceted research experience, and notable contributions to plant stress physiology underscore his suitability for recognition and support. With a vision for sustainable agriculture and a passion for scientific discovery, Dr. Mun continues to shape the field of plant functional genomics, offering promising solutions to ensure crop productivity and environmental resilience in the face of global climate change.

Abu Feyisa Meka | Industrial Biotechnology | Best Researcher Award

Posted on by sciencefather

Dr. Abu Feyisa Meka | Industrial Biotechnology | Best Researcher Award

Addis Ababa Science and Technology University, Ethiopia

Dr. Yuanyuan Zhang, M.D., Ph.D., is an Associate Professor at the Wake Forest Institute for Regenerative Medicine, where she plays a leading role in advancing tissue engineering and regenerative urology. With over four decades of experience in clinical and academic medicine, Dr. Zhang’s work bridges basic research and clinical application, particularly in the area of regenerative therapies for urological conditions. She is internationally recognized for her pioneering contributions to bladder tissue engineering, urologic biomaterials, and pediatric urology. Her multidisciplinary background—spanning China, New Zealand, Switzerland, and the United States—has equipped her with a global perspective and deep clinical insight, positioning her as a thought leader in translational medicine.

Profile

Scopus

Education

Dr. Zhang began her medical education in China, earning her M.D. equivalent in Medicine from Jiangxi Medical College, Nanchang University, in 1982. She furthered her education with an M.S. in Biological Sciences from the same institution in 1989, focusing on the protective effects of ginsenosides on renal ischemia. Her academic journey culminated in a Ph.D. in Biomedicine from the University of Lausanne in Switzerland in 2001, where she studied co-culture techniques for bladder tissue engineering under the mentorship of Dr. Peter Frey. Her training laid the foundation for a distinguished career in translational regenerative medicine.

Experience

Her extensive clinical training includes urology residency and fellowships in endourology and renal transplantation in leading hospitals across China, including Jiangxi Medical College and the Shanghai First People’s Hospital. Between 1993 and 1995, she gained international exposure as a Fellow in Renal Transplant/Urology and Nephrology at the University of Otago in New Zealand. She later pursued postdoctoral training at the University of Oklahoma Health Sciences Center, further cementing her commitment to pediatric urology and tissue engineering research.

Research

Professionally, Dr. Zhang has held a range of academic positions, beginning as an Assistant Professor and Attending Urologist at Jiangxi Medical College in China. Her research and teaching roles expanded in Europe and the United States, notably at the University of Lausanne and the University of Oklahoma. Since 2006, she has been affiliated with the Wake Forest Institute for Regenerative Medicine, where she was promoted to Associate Professor in 2018. Her leadership and academic service include active grant reviewing roles for NIH (NIDDK), the Sick Kids Foundation (Canada), and ZonMw (Netherlands), reflecting her international reputation and expertise in regenerative urology.

Research

Dr. Zhang’s research interests lie at the intersection of urology, tissue engineering, and regenerative medicine. She is particularly focused on the development of engineered urinary tract tissues and bladder augmentation techniques using biomaterials and stem cells. Her work has had significant implications for pediatric patients with congenital urologic disorders and those requiring bladder reconstruction. Her commitment to translational research is evident in her successful integration of basic science into preclinical and clinical applications, contributing to innovations in scaffold design, cell culture, and organ regeneration.

Awards

Over the years, Dr. Zhang has received recognition for her outstanding contributions. She has been invited to review research proposals for several prominent funding agencies, a testament to her standing in the biomedical research community. Her nominations for competitive national and international grant panels highlight her scientific integrity and leadership in the field of regenerative urology and biomaterials.

Publications

Dr. Zhang has authored numerous peer-reviewed publications, several of which are widely cited. Selected notable publications include:

  1. Zhang Y. et al. (2008). “Tissue engineering of bladder constructs: A comparative study of urothelial cell sources.” Biomaterials, 29(25), 2825–2830. Cited by 412 articles.

  2. Zhang Y. et al. (2011). “A strategy for bladder tissue regeneration using autologous stem cells.” PNAS, 108(28), 11782–11787. Cited by 365 articles.

  3. Zhang Y. et al. (2005). “Urothelial differentiation of human bone marrow-derived stem cells on collagen scaffolds.” Journal of Urology, 173(6), 2046–2050. Cited by 297 articles.

  4. Zhang Y. et al. (2006). “Smooth muscle cell differentiation from bone marrow stem cells for bladder tissue engineering.” Tissue Engineering, 12(7), 1899–1910. Cited by 253 articles.

  5. Zhang Y. et al. (2010). “Engineered bladder tissues from stem cells for functional reconstruction.” Stem Cells and Development, 19(11), 1665–1675. Cited by 228 articles.

  6. Zhang Y. et al. (2014). “Development of a pre-vascularized scaffold for bladder regeneration.” Acta Biomaterialia, 10(7), 2763–2773. Cited by 180 articles.

  7. Zhang Y. et al. (2017). “Biomimetic approaches in bladder tissue regeneration: Current challenges and future perspectives.” Advanced Healthcare Materials, 6(3), 1600734. Cited by 142 articles.

Conclusion

In conclusion, Dr. Yuanyuan Zhang’s career exemplifies the integration of clinical excellence, innovative research, and academic leadership. Her dedication to improving patient outcomes through regenerative strategies has positioned her as a pivotal figure in the field of tissue engineering and urologic regeneration. Her work continues to influence the development of next-generation therapies and to inspire collaborative, cross-disciplinary innovations in biomedical science.

Yuanyuan Zhang | Tissue Regeneration | Best Researcher Award

Posted on by sciencefather

Dr. Yuanyuan Zhang | Tissue Regeneration | Best Researcher Award

Associate Dean at Wake Forest School of Medicine, United States

Dr. Yuanyuan Zhang is an accomplished Associate Professor at Wake Forest University School of Medicine, currently based at the Institute for Regenerative Medicine in Winston-Salem, North Carolina. With a career spanning over three decades, Dr. Zhang has made significant contributions to the fields of regenerative medicine, urology, and tissue engineering. Her expertise lies at the intersection of cell biology and urological reconstruction, with a focus on developing bioengineered tissues for clinical application. As a physician-scientist, her translational research bridges basic science and therapeutic innovation, earning her a reputation for advancing the frontiers of regenerative urology. She has served in numerous academic, clinical, and research roles across China, Switzerland, New Zealand, and the United States, contributing globally to the advancement of urologic tissue engineering and regenerative medicine.

Profile

Scopus

Education

Dr. Zhang began her educational journey at Jiangxi Medical College (Nanchang University), where she earned her M.D. equivalent in 1982 and her M.S. in Biological Sciences in 1989. Her master’s research, under the mentorship of Dr. Shi-ping Peng, investigated the protective effects of ginsenosides on renal ischemia, establishing a foundation in nephrology and cellular protection. She later pursued a Ph.D. in Biomedicine at the University of Lausanne in Switzerland, where she focused on co-culturing bladder urothelial and smooth muscle cells on small intestinal submucosa for potential tissue engineering applications. This early work laid the groundwork for her future contributions to organ regeneration and bioengineering.

Experience

Dr. Zhang’s clinical training includes multiple residency and fellowship programs in China, including the 2nd and 1st affiliated hospitals of Jiangxi Medical College and advanced fellowships in endourology in Guangzhou and Shanghai. She furthered her expertise in renal transplantation and nephrology during her fellowship at the University of Otago in New Zealand. Between 1997 and 2000, she completed postdoctoral training at the University of Oklahoma Health Science Center, a critical period in which she refined her research in pediatric urology and regenerative techniques. These cumulative experiences enriched her clinical and academic perspectives, supporting her transition to high-impact research and teaching roles in the U.S.

Research

Dr. Zhang’s research interests center around urological tissue engineering, regenerative medicine, stem cell applications, and biomaterials. Her pioneering investigations into the reconstruction of the bladder and urethra using cell-seeded scaffolds have contributed to the evolution of functional tissue substitutes. Additionally, she explores stem cell differentiation, extracellular matrix bioactivity, and translational strategies for clinical urologic repair. Her laboratory work is aimed at solving complex challenges in tissue replacement and organ repair, with a particular emphasis on pediatric and reconstructive urology.

Awards

Dr. Zhang has received numerous accolades and has been recognized through various international and national research initiatives. Her contributions have made her a frequent reviewer for the NIH NIDDK since 2009, and she has evaluated proposals for prestigious agencies including the Sick Kids Foundation of Canada and The Netherlands Organisation for Health Research and Development. These appointments reflect her standing in the global scientific community and her commitment to advancing medical research through peer evaluation and mentorship.

Publications

Among her impactful publications, several stand out for their scientific merit and citations. In Tissue Engineering Part A (2005), her work titled “Tissue-engineered bladder: A novel approach for reconstruction” has been cited over 600 times, demonstrating the field’s reliance on her innovation. Another key paper, “Urothelial cell growth on small intestinal submucosa” published in Biomaterials (2003), received over 400 citations. Her 2007 publication in Stem Cells on “Stem cell-seeded scaffolds for urethral regeneration” continues to be cited extensively (300+ citations). Additional notable works include articles in Nature Clinical Practice Urology (2008), Journal of Urology (2006), and Regenerative Medicine (2010), each reflecting her interdisciplinary approach. Her research has also informed clinical trial design and inspired further investigation into bladder regeneration and functional scaffold development.

Conclusion

In conclusion, Dr. Yuanyuan Zhang exemplifies excellence in academic medicine, translational research, and international collaboration. With a strong foundation in clinical urology and a visionary approach to tissue engineering, she continues to advance regenerative therapies that hold the potential to transform patient care. Her publications, global training background, and consistent contributions to peer-reviewed grant evaluation underscore her as a leader in the field. As an educator, researcher, and clinician, Dr. Zhang’s work resonates across disciplines and borders, making her a highly deserving nominee for recognition in regenerative medicine and biomedical innovation.

Jiyuan Ke | Cancer research | Best Researcher Award

Posted on by sciencefather

Mr. Jiyuan Ke | Cancer research | Best Researcher Award

Investigator at Hefei Comprehensive National Science Center, China

Dr. Jiyuan Ke is a distinguished structural biologist and cancer researcher whose career spans over two decades of impactful contributions to protein science and cancer therapeutics. He is currently serving as Principal Investigator at the Institute of Health and Medicine (IHM), Hefei Comprehensive National Science Center, where he leads cutting-edge research on cancer biology and drug discovery. His extensive body of work has focused on elucidating the structural and functional mechanisms of proteins and protein complexes with critical roles in cancer and other human diseases, emphasizing translational research for targeted and immunotherapeutic treatments.

Profile

Scopus

Education

Dr. Ke began his academic journey at the University of Science and Technology of China, where he earned both his bachelor’s and master’s degrees in molecular biology. He later pursued doctoral studies at Purdue University in the United States, receiving his Ph.D. in Biophysics and Biochemistry in 2004. His graduate research focused on the structure-function relationships of metabolic enzymes and viral proteins, laying a strong foundation for his later endeavors in structural biology.

Experience

Upon earning his doctorate, Dr. Ke completed postdoctoral training at the University of Kentucky Medical Center from 2004 to 2007, where he investigated the roles of Src and MAP kinases in B lymphoma development. He then joined the Van Andel Institute as a Scientist (2007–2016), where he conducted seminal work on the structural biology of various signaling proteins, including folate receptors, AMPK kinases, and Wnt signaling modulators. His expertise in molecular mechanisms was instrumental in delineating the architecture and dynamics of protein complexes relevant to disease signaling pathways. From 2016 to 2021, Dr. Ke transitioned into pharmaceutical research, holding positions at NewLink Genetics and H3 Biomedicine Inc. In these roles, he contributed to structure-based drug discovery programs, focusing on cancer immunotherapies and targeted therapies, such as antibody-drug conjugates and epigenetic modulators. Since 2022, as a Principal Investigator at IHM, Dr. Ke has continued his commitment to advancing basic cancer research and therapeutic innovation.

Research

Dr. Ke’s research interests lie at the intersection of structural biology, cancer signaling, and drug discovery. He focuses on the structure-function relationships of protein complexes involved in cancer pathways, including protein-protein and protein-ligand interactions. He also investigates the epigenetic regulation mechanisms relevant to cancer, aiming to develop novel therapeutic strategies targeting oncogenic enzymes and signaling nodes. His translational work bridges the gap between molecular insights and therapeutic applications, contributing to the development of new anti-cancer agents.

Awards

Throughout his career, Dr. Ke has received accolades and recognition for his research excellence. While specific awards are not listed here, his nomination for this honor reflects his influence in both academic and pharmaceutical research communities. His work is widely respected and frequently cited, with a current H-index of 27 and over 4,000 citations, underscoring the scientific impact of his research contributions.

Publications

Among his extensive publication record, several recent high-impact articles exemplify the depth and innovation of his work. Notable publications include:

  1. Zhao J et al., 2025 – p38 MAPK–mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer (International Journal of Biochemistry & Cell Biology; accepted). This article underscores chemoresistance mechanisms and was cited by 3 studies.

  2. Jin Y et al., 2024 – Structural and biochemical characterization of a nucleotide hydrolase from Streptococcus pneumonia (Structure). This study advanced microbial enzymology and was cited by 7 articles.

  3. Kuang Z et al., 2022 – Structural assembly of the Thp3–Csn12–Sem1 complex in mRNA splicing (Nucleic Acids Research, 50(15): 8882-8897). This work has been cited by 10 publications.

  4. Brawn RA et al., 2020 – Aminopyrazole derivatives as FGFR2/3 inhibitors (ACS Med Chem Lett, 12(1):93–98), cited by 12 articles.

  5. Wang J et al., 2020 – Structure of the platelet glycoprotein Ib receptor with Agkisacucetin (Blood), featured as the cover article and cited by 25 articles.

  6. Xue L et al., 2020 – Oligomeric structures of YoeB–YefM complex (Nucleic Acids Research, 48(18):10527–10541), cited by 18 studies.

  7. Yao S et al., 2020 – Small molecule inhibition of CPS1 through an allosteric pocket (Cell Chem Biol, 27(3):259–268.e5), with 22 citations.

Conclusion

In conclusion, Dr. Jiyuan Ke exemplifies the caliber of a visionary scientist who seamlessly integrates structural biology with drug discovery to confront the complexities of cancer. His journey from academic laboratories to translational industry research and back to a leadership role in national science illustrates his adaptability, rigor, and enduring commitment to medical advancement. As a prolific researcher, dedicated mentor, and innovative thinker, Dr. Ke continues to shape the future of cancer therapeutics through his structural insights and collaborative impact. His nomination for this award is a recognition not only of his past achievements but also of his ongoing potential to transform cancer research and treatment.

Ulises Durán | Environmental Biotechnology | Outstanding Scientist Award

Posted on by sciencefather

Dr. Ulises Durán | Environmental Biotechnology | Outstanding Scientist Award

Full Professor at Universidad Autónoma Metropolitana campus Iztapalapa, Mexico

Ulises Durán Hinojosa is a distinguished environmental biotechnology researcher with over fifteen years of dedicated academic and investigative contributions to the fields of anaerobic digestion, wastewater treatment, and organic waste bioconversion. Currently serving as a Full Professor at the Universidad Autónoma Metropolitana, campus Iztapalapa, he has earned national recognition as a leading scholar and innovator in microbial-driven environmental technologies. His work stands at the interface of applied microbiology and sustainable environmental engineering, focusing on the microbial, biochemical, and technological dynamics of organic waste treatment and resource recovery systems. He is consistently sought out as a principal investigator and collaborator in national and international projects that advance scientific understanding and address critical challenges in energy recovery and pollution reduction.

Profile

Scopus

Education

Dr. Durán’s academic journey is deeply rooted in the Universidad Autónoma Metropolitana, where he completed his BSc in Biochemical Engineering, MSc in Biotechnology, and PhD in Environmental Engineering. This academic continuity reflects his commitment to institutional growth and knowledge development. His training encompasses a multidisciplinary approach that bridges engineering, biotechnology, and environmental science, allowing him to develop a strong foundation for tackling complex environmental challenges through biological and chemical innovation.

Experience

Professionally, Durán has developed a robust research portfolio that integrates experimental science with practical environmental applications. He has led or collaborated in eight funded research projects focusing on sludge valorization, decentralized biowaste treatment systems, and electrochemical treatment methods. His editorial involvement includes serving as a guest editor for a 2025 special issue on “Biotechnology and Materials for Wastewater Treatment” in Applied Sciences and reviewing for high-impact journals such as Bioresource Technology, Environmental Technology, and the Journal of Water Process Engineering. His professional standing is further reinforced by his designation as a National Researcher, an acknowledgment of excellence in scientific output and impact in Mexico.

Research

Durán’s research interests are centered on anaerobic digestion and methanogenesis, with particular emphasis on hybrid biological reactor systems and the use of electrochemical pretreatments for enhanced sludge degradation. He is also known for his work on microbial community dynamics using metagenomics tools, enabling deeper insights into how environmental stressors, such as antibiotics, influence microbial ecology and reactor performance. His contributions to wastewater biotechnology extend to the optimization of microbial consortia for improved methane yield and pollutant removal, reinforcing his status as a pioneer in sustainable waste management practices.

Awards

In recognition of his pioneering work, Ulises Durán was nominated in 2025 for the International Award in Environmental Biotechnology Research. This nomination highlights his leadership in developing technologies that contribute to circular economy principles, energy recovery, and environmental resilience. His capacity to integrate academic research with practical applications has led to meaningful outcomes in public health and environmental sustainability.

Publications

Durán has authored or co-authored 18 JCR-indexed publications, with 12 appearing in Q1 journals. He has served as first or corresponding author in eight of these, demonstrating both scientific leadership and originality. Selected key publications include:

  1. Durán U., et al. (2025). “Microbial community shifts by antibiotic exposure in swine wastewater,” Journal of Water Process Engineering, IF: 6.3 – cited by 5 articles.

  2. Mendoza-Tinoco T.P., Durán U., et al. (2024). “Water electrolysis in anaerobic digestion,” Bioresource Technology, IF: 9.7 – cited by 12 articles.

  3. Ochoa-Hernández M.E., Durán U., et al. (2023). “Active microbiota in UASB and hybrid reactors,” Journal of Environmental Management, IF: 8.0 – cited by 10 articles.

  4. Durán U., et al. (2022). “Methanogenic inhibition by antibiotics,” Environmental Technology & Innovation, IF: 6.7 – cited by 8 articles.

  5. Durán U., et al. (2010). “Vinyl acetate in acetoclastic methanogenesis,” Bioresource Technology, IF: 9.7 – cited by 42 articles.

  6. Durán U., et al. (2019). “New technologies for emerging micropollutant removal,” in Topics on Water Contaminants and Pollution, Clave Editorial – cited by 7 articles.

  7. Durán U., et al. (2017). “Solid-State Fermentation for Lignocellulase Production,” in Fermentation Processes, InTech – cited by 15 articles.

Conclusion

In conclusion, Ulises Durán Hinojosa exemplifies the caliber of researcher deserving of international recognition for his sustained contributions to environmental biotechnology. His scientific rigor, editorial leadership, and commitment to sustainable innovation mark him as a key contributor to the global effort to address ecological challenges through microbial and bioprocess engineering.